Insulin-like growth factor 2 drives fibroblast-mediated tumor immunoevasion and confers resistance to immunotherapy
Journal of Clinical Investigation · 15.11.2024 · 134 (22)
DOI: 10.1172/jci183366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.11.2024. Verfasst von Daqiang Song und 22 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Insulin-Like Growth Factor II, Cancer-Associated Fibroblasts, Receptor, IGF Type 1. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing, Chongqing medical scientific research project/Joint project of Chongqing Health Commission and Science and Technology Bureau.
Abstract (Originalsprache)
T cell exclusion is crucial in enabling tumor immune evasion and immunotherapy resistance. However, the key genes driving this process remain unclear. We uncovered a notable increase of insulin-like growth factor 2 (IGF2) in immune-excluded tumors, predominantly secreted by cancer-associated fibroblasts (CAFs). Using mice with systemic or fibroblast-specific deletion of IGF2, we demonstrated that IGF2 deficiency enhanced the infiltration and cytotoxic activity of CD8 + T cells, leading to a reduction in tumor burden. Integration of spatial and single-cell transcriptomics revealed that IGF2 promoted interaction between CAFs and T cells via CXCL12 and programmed death ligand 1 (PD-L1). Mechanistically, autocrine IGF2 activated PI3K/AKT signaling by binding to the IGF1 receptor (IGF1R) on CAFs, which was required for the immunosuppressive functions of CAFs. Furthermore, genetic ablation of IGF2 or targeted inhibition of the IGF2/IGF1R axis with the inhibitor linsitinib markedly boosted the response to immune checkpoint blockade. Clinically, elevated levels of IGF2 in tumors or plasma correlated with an adverse prognosis and reduced efficacy of anti–programmed death 1 treatment. Together, these results highlight the pivotal role of IGF2 in promoting CAF-mediated immunoevasion, indicating its potential as a biomarker and therapeutic target in immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Pharmacology, Chongqing Medical University, Chongqing, China.
- Department of Oncology.
- Department of Breast and Thyroid Surgery, and.
- Department of Respiratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Chongqing medical scientific research project/Joint project of Chongqing Health Commission and Science and Technology Bureau
- Chongqing Graduate Tutor Team Construction Project, Chongqing Education Commission Foundation
- CQMU Program for Youth Innovation in Future Medicine
Zitieren
APA
Song, D., Wu, Y., Li, J., Liu, J., Yi, Z., Wang, X., Sun, J., Li, L., Wu, Q., Chen, Y., Fang, H., Luan, T., Du, H., Huang, J., Peng, W., Wei, Y., Li, F., Li, Q., Zhang, L., …, & Li, H. (2024). Insulin-like growth factor 2 drives fibroblast-mediated tumor immunoevasion and confers resistance to immunotherapy. Journal of Clinical Investigation, 134(22). https://doi.org/10.1172/jci183366
Vancouver
Song D, Wu Y, Li J, Liu J, Yi Z, Wang X, et al. Insulin-like growth factor 2 drives fibroblast-mediated tumor immunoevasion and confers resistance to immunotherapy. Journal of Clinical Investigation. 2024;134(22). doi:10.1172/jci183366
BibTeX
@article{Song2024,
author = {Song, Daqiang and Wu, Yushen and Li, Jie and Liu, Jiazhou and Yi, Ziying and Wang, Xiaoyu and Sun, Jiazheng and Li, Liuying and Wu, Qianxue and Chen, Yuru and Fang, Huiying and Luan, Tiankuo and Du, Huimin and Huang, Jing and Peng, Weiyan and Wei, Yuxian and Li, Fan and Li, Qin and Zhang, Li and Zhu, Yong and Wan, Jingyuan and Ren, Guosheng and Li, Hongzhong},
title = {Insulin-like growth factor 2 drives fibroblast-mediated tumor immunoevasion and confers resistance to immunotherapy},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {22},
doi = {10.1172/jci183366}
}
EUVIMED